These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19818587)

  • 1. Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.
    Arhin FF; McKay GA; Beaulieu S; Sarmiento I; Parr TR; Moeck G
    Int J Antimicrob Agents; 2009 Dec; 34(6):550-4. PubMed ID: 19818587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus.
    Arhin FF; Sarmiento I; Parr TR; Moeck G
    Int J Antimicrob Agents; 2012 Feb; 39(2):159-62. PubMed ID: 22070858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2014 Jul; 44(1):65-8. PubMed ID: 24906505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
    Vidaillac C; Parra-Ruiz J; Rybak MJ
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
    Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ
    Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
    Vaudaux P; Huggler E; Arhin FF; Moeck G; Renzoni A; Lew DP
    Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Sweeney D; Shinabarger DL; Arhin FF; Belley A; Moeck G; Pillar CM
    Diagn Microbiol Infect Dis; 2017 Feb; 87(2):121-128. PubMed ID: 27890418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial and rapid bactericidal activities of sitafloxacin and other agents against Streptococcus pyogenes].
    Namba E; Okumura R; Chiba M; Hoshino K; Tateda K
    Jpn J Antibiot; 2013 Oct; 66(5):293-304. PubMed ID: 24527519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.
    Arhin FF; McKay GA; Beaulieu S; Sarmiento I; Parr TR; Moeck G
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):207-10. PubMed ID: 19748436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.
    Morrissey I; Seifert H; Canton R; Nordmann P; Stefani S; Macgowan A; Janes R; Knight D;
    J Antimicrob Chemother; 2013 Jan; 68(1):164-7. PubMed ID: 22941898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
    Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
    Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Coyle EA; Rybak MJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):706-9. PubMed ID: 11181347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
    Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
    Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative in vitro activity of new oral macrolides against Streptococcus pyogenes strains].
    Prado V; Romero J; Herrera N; Marinkovic K; Bustos R
    Rev Med Chil; 1993 Oct; 121(10):1128-34. PubMed ID: 8191116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
    Zhanel GG; Yachison C; Nichol K; Adam H; Noreddin AM; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2012 Jul; 67(7):1706-11. PubMed ID: 22467630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of propolis special extract GH 2002 against multidrug-resistant clinical isolates.
    Astani A; Zimmermann S; Hassan E; Reichling J; Sensch KH; Schnitzler P
    Pharmazie; 2013 Aug; 68(8):695-701. PubMed ID: 24020127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of human serum albumin on oritavancin in vitro activity against enterococci.
    McKay GA; Beaulieu S; Sarmiento I; Arhin FF; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2687-9. PubMed ID: 19349514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.